Comment

. 2021 May 1;397(10285):1599-1601.

doi: 10.1016/S0140-6736(21)00712-1.

Tocilizumab in COVID-19: some clarity amid controversy

Shruti Gupta¹, David E Leaf²

Affiliations

¹ Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sgupta21@bwh.harvard.edu.
² Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA.

PMID: 33933194
PMCID: PMC8084409
DOI: 10.1016/S0140-6736(21)00712-1

Comment

Tocilizumab in COVID-19: some clarity amid controversy

Shruti Gupta et al. Lancet. 2021.

. 2021 May 1;397(10285):1599-1601.

doi: 10.1016/S0140-6736(21)00712-1.

Authors

Shruti Gupta¹, David E Leaf²

Affiliations

¹ Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sgupta21@bwh.harvard.edu.
² Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA.

PMID: 33933194
PMCID: PMC8084409
DOI: 10.1016/S0140-6736(21)00712-1

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Comment in

Allocated but not treated: the silent 16.
Lee TC, Morris AM, Schwartz IS, McDonald EG. Lee TC, et al. Lancet. 2022 May 7;399(10337):1775. doi: 10.1016/S0140-6736(22)00377-4. Lancet. 2022. PMID: 35526549 Free PMC article. No abstract available.

Comment on

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.

Cited by

I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections.
Pandrea I, Brooks K, Desai RP, Tare M, Brenchley JM, Apetrei C. Pandrea I, et al. Front Immunol. 2022 Aug 12;13:899559. doi: 10.3389/fimmu.2022.899559. eCollection 2022. Front Immunol. 2022. PMID: 36032119 Free PMC article. Review.
Persistence is key: unresolved immune dysfunction is lethal in both COVID-19 and non-COVID-19 sepsis.
An AY, Baghela A, Zhang P, Falsafi R, Lee AH, Trahtemberg U, Baker AJ, Dos Santos CC, Hancock REW. An AY, et al. Front Immunol. 2023 Sep 26;14:1254873. doi: 10.3389/fimmu.2023.1254873. eCollection 2023. Front Immunol. 2023. PMID: 37822940 Free PMC article.
Immune-Mediated Mechanisms of COVID-19 Neuropathology.
Dunai C, Collie C, Michael BD. Dunai C, et al. Front Neurol. 2022 May 19;13:882905. doi: 10.3389/fneur.2022.882905. eCollection 2022. Front Neurol. 2022. PMID: 35665037 Free PMC article. Review.
Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury.
Moussavi-Harami SF, Cleary SJ, Magnen M, Seo Y, Conrad C, English BC, Qiu L, Wang KM, Abram CL, Lowell CA, Looney MR. Moussavi-Harami SF, et al. J Clin Invest. 2024 Oct 1;134(24):e183161. doi: 10.1172/JCI183161. J Clin Invest. 2024. PMID: 39352872 Free PMC article.
Future applications of host direct therapies for infectious disease treatment.
Thom RE, D'Elia RV. Thom RE, et al. Front Immunol. 2024 Oct 1;15:1436557. doi: 10.3389/fimmu.2024.1436557. eCollection 2024. Front Immunol. 2024. PMID: 39411713 Free PMC article. Review.

See all "Cited by" articles

References

1. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643. - PMC - PubMed
1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed
1. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975. - PMC - PubMed
1. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with covid-19. JAMA Intern Med. 2021;181:41–51. - PMC - PubMed
1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383:2333–2344. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tocilizumab in COVID-19: some clarity amid controversy

Affiliations

Tocilizumab in COVID-19: some clarity amid controversy

Authors

Affiliations

Figures

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources